It is known that hyperactivation of KRAS stimulates the downstream AKT and ERK pathways, which were reported to attenuate resistance to chemo-agents in carcinomas [33], therefore, whether BI-2865 reversed MDR through activating AKT and ERK pathways was further identified here. The gene discussed is KRAS; the disease is carcinoma.